BioGaia announced that Theresa Agnew begins her role on 25 September 2023, as the Chief Executive Officer of BioGaia. As previously communicated, Theresa Agnew has 20-years of experience in various leadership roles within consumer healthcare, over-the-counter (OTC) drugs, and medical devices from leading companies such as GlaxoSmithKline (GSK), Essilor, and Johnson & Johnson.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
125.5 SEK | +10.48% | +6.70% | +24.31% |
09:30am | Transcript : BioGaia AB, Q1 2024 Earnings Call, May 07, 2024 | |
08:00am | BioGaia AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.31% | 1.06B | |
-2.47% | 88.14B | |
+1.45% | 40.44B | |
-14.43% | 32.24B | |
+52.98% | 24.39B | |
-14.85% | 15.59B | |
-13.87% | 12.14B | |
-7.87% | 12.18B | |
-39.40% | 12.3B | |
+5.39% | 8.87B |
- Stock Market
- Equities
- BIOG B Stock
- News BioGaia AB
- Biogaia AB Appoints Theresa Agnew as CEO